Overall | Simultaneous PET and MRI acquisition (precise registration of MRI and PET) |
| One-stop local and whole-body staging |
| Decreased ionizing radiation |
| Reduced number of total examinations |
| Better characterization of incidental findings |
| More accurate measurement of lesions than with unenhanced CT |
Lymphoma | Increased sensitivity to detect bone marrow involvement |
| Avoidance of core biopsy if PET/MRI results are negative |
| Reduced dose of ionizing radiation (particularly important for patients with therapy-refractory disease who need multiple scans to closely monitor treatment efficacy) |
Neurofibromatosis 1 and MPNST | Detailed depiction of peripheral neurofibromata and central nervous system |
| Optimal alignment of MRI and PET in cases of multiple neurofibromas |
| Comprehensive examination of central nervous system and peripheral lesions in single examination |
Sarcoma | Better characterization of bones and soft tissues |
| Higher sensitivity for bone marrow metastases |
| Improved monitoring of pediatric tumors after immunotherapy |